Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
Avenue Therapeutics將參加Maxim集團的2024年醫療保健虛擬峯會
MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group's 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET.
邁阿密，2024年10月9日（環球新聞專線）——專注於神經系統疾病治療療法開發和商業化的專業製藥公司Avenue Therapeutics, Inc.（納斯達克股票代碼：ATXI）（「Avenue」 或 「公司」）今天宣佈，Avenue Therapeutics首席執行官亞歷山德拉·麥克萊恩萬德將參加Maxim集團2024年醫療保健虛擬峯會的爐邊談話美國東部時間 2024 年 10 月 15 日星期二下午 1:30
The fireside chat will be available to registered attendees. Investors may sign-up or log-in to the conference here.
爐邊聊天將可供註冊的與會者參加。投資者可以在此處註冊或登錄會議。
About Avenue Therapeutics
Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. It is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABAA α2, α3 receptor positive allosteric modulator for CNS diseases, and IV tramadol for the management of acute postoperative pain in adults in a medically supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit .
關於 Avenuetics
Avenue Therapeutics, Inc.（納斯達克股票代碼：ATXI）是一家專業製藥公司，專注於神經系統疾病治療療法的開發和商業化。它目前正在開發三種資產，包括脊柱和延髓肌萎縮的同類首創資產 AJ201、用於治療中樞神經系統疾病的口服小分子選擇性GABAA α2、α3受體陽性變構調節劑，以及用於在醫學監督的醫療保健環境中管理成人急性術後疼痛的靜脈曲馬多。BAER-101Avenue總部位於佛羅里達州邁阿密，由豐澤生物技術公司（納斯達克股票代碼：FBIO）創立。欲了解更多信息，請訪問。
Contact:
Jaclyn Jaffe
Avenue Therapeutics, Inc.
(781) 652-4500
ir@avenuetx.com
聯繫人：
Jaclyn Jaffe
大道療法有限公司
(781) 652-4500
ir@avenuetx.com
Released October 9, 2024
2024 年 10 月 9 日發佈
譯文內容由第三人軟體翻譯。
